57734-57-3

Usage

General Description

(2-Pyrrolidinyl)methylamine, also known as PMMA, is a chemical compound with the formula C6H13N. It is a tertiary amine with a pyrrolidine ring, and it has a variety of industrial and research applications. PMMA is commonly used as a building block for the synthesis of other chemicals, including pharmaceuticals and agrochemicals. It is also used in the production of polymers, plastics, and organic coatings. PMMA is a colorless liquid with a strong odor, and it is considered to be a hazardous substance that should be handled with caution. It is important to use proper safety precautions when working with PMMA to ensure the health and safety of individuals and the environment.

InChI:InChI=1/C5H12N2/c6-4-5-2-1-3-7-5/h5,7H,1-4,6H2

Upstream product

• 64608-72-6 (1H-pyrrol-2-yl)methylamine 
• 108-24-7 acetic anhydride 
• 30130-35-9 N-acetylprolinamide 
• 960622-17-7 (E)-pyrrole-2-carboxaldehyde oxime 
• 1003-29-8 2-pyrrole aldehyde 
• 2812-47-7 pyrrolidine-2-carboxylic acid amide 
• 259537-92-3 tert-butyl (2R)-2-(aminomethyl)pyrrolidine-1-carboxylate 
• 62937-47-7 (2R)-2-carbamoyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 344-25-2 D-Prolin 
• 6404-31-5 Z-D-proline 
• 62937-45-5 (R)-prolinamide 

Downstream Products

• 88327-63-3 2,3-dioxo-1,4-diazabicyclo<4.3.0>nonane 
• 685126-24-3 3-{2-[2-(5-bromo-2-methoxy-phenyl)-ethyl]-3-chloro-phenyl}-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]imidazole 
• 88327-66-6 4-ethyl-1,4-diazabicyclo<4.3.0>nonane 
• 88327-70-2 4-(2-oxo-4-n-butyl)-1,4-diazabicyclo<4.3.0>nonane 
• 88327-68-8 4-(β-phen yl-β-hydroxyethyl)-1,4-diazabicyclo<4.3.0>nonane 
• 88327-69-9 1-(Hexahydro-pyrrolo[1,2-a]pyrazin-2-yl)-3-phenoxy-propan-2-ol 
• 5654-83-1 octahydropyrrolo[1,2-a]pyrazine 
• 88327-67-7 4-(β-phenylethyl)-1,4-diazabicyclo<4.3.0>nonane 
• 2856-81-7 1-(4-fluoro-phenyl)-4-(hexahydro-pyrrolo[1,2-a]pyrazin-2-yl)-butan-1-one 
• 1206103-64-1 (4aS,13aR)-8-bromo-10-[(phenylmethyl)oxy]-2,3,4a,5,13,13a-hexahydro-1H-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazine-9,11-dione 
• 956467-82-6 N-[((2R)-1-{[3,4-bis(methyloxy)phenyl]sulfonyl}-2-pyrrolidinyl)methyl]-3,4-bis(methyloxy)benzenesulfonamide 
• 956468-16-9 N-[((2R)-1-{[3,4-bis(methyloxy)phenyl]sulfonyl}-2-pyrrolidinyl)methyl]-3,4-bis(methyloxy)benzenesulfonamide 

Relevant academic research and scientific papers

Enantioselective Synthesis of 2-Aminomethyl and 3-Amino Pyrrolidines and Piperidines through 1,2-Diamination of Aldehydes

An efficient method for the synthesis of 1,2-diamines from aldehydes through proline-catalyzed asymmetric α-amination followed by reductive amination is reported. The products resemble those obtained through direct asymmetric diamination of terminal alkenes. The methodology is used to synthesize 2-aminomethyl and 3-amino pyrrolidines and piperidines in high yields and with a good enantioselectivity. The usefulness of the method is demonstrated through the synthesis of a 2-aminomethyl iminocyclitol.

Biomimetic asymmetric Michael addition reactions in water catalyzed by amino-containing β-cyclodextrin derivatives

Nine β-cyclodextrin derivatives containing an amino group were synthesized via nucleophilic substitution from mono(6-O-p-tolylsulfonyl)-β-cyclodextrin and used in asymmetric biomimetic Michael addition reactions in water at room temperature. The mechanism responsible for the moderate activity and enantioselectivity of the β-cyclodextrin derivatives was explored using nuclear magnetic resonance spectroscopy, namely 2D 1H rotating-frame overhauser effect spectroscopy (ROESY), ultraviolet absorption spectroscopy, and quantum chemical calculations, which provide a useful technique for investigating the formation of inclusion complexes. The effects of the pH of the reaction medium, the β-cyclodextrin derivative dosage, the structure of the modifying amino group, and various substrates on the yield and enantioselectivity were investigated. The results indicated that these factors had an important effect on the enantiomeric excess (ee) in the reaction system. Experiments using a competitor for inclusion complex formation showed that a hydrophobic cavity is necessary for enantioselective Michael addition. A comparison of the reactions using 4-nitro-β-nitrostyrene and 2-nitro-β-nitrostyrene showed that steric hindrance improved the enantioselectivity. This was verified by the optimized geometries obtained from quantum chemical calculations. An ee of 71% was obtained in the asymmetric Michael addition of cyclohexanone and 2-nitro-β-nitrostyrene, using (S)-2-aminomethylpyrrolidine-modified β-CD as the catalyst, in an aqueous buffer solution, i.e., CH3COONa-HCl (pH 7.5).

Biomimetic asymmetric aldol reactions catalyzed by proline derivatives attached to β-cyclodextrin in water

Two proline derivatives, (S)-2-aminomethylpyrrolidine and (R)-2-aminomethylpyrrolidine modified β-CD (CD-1, CD-2) were synthesized in the yields of 31% and 14%. Their self-inclusion conformations were characterized by 1H ROESY NMR studies and q

Synthesis, characterisation and in vitro cytotoxicity studies of a series of chiral platinum(II) complexes based on the 2-aminomethylpyrrolidine ligand: X-ray crystal structure of [PtCl2(R-dimepyrr)] (R-dimepyrr = N-dimethyl-2(R)-aminomethylpyrrolidine)

A series of platinum(II) complexes were synthesised based on the enantiomerically pure amino acid proline. Novel synthetic pathways were developed, adapted from standard peptide chemistry, to produce the 2-aminomethylpyrrolidine (pyrr) ligand and its derivatives with differing arrangements of methyl substituents at the exocyclic amine sites. The crystal structure of [PtCl2(R-dimepyrr)] (R-dimepyrr = N,N-dimethyl-2(R)-aminomethylpyrrolidine) is reported and the five-membered ligand ring has been shown to be in an envelope conformation. Cytotoxicity studies were carried out on the ovarian cancer A2780 tumour cell line and its cisplatin-resistant variant, A2780cisR. Remarkably good activity was seen for several of the drugs when compared to cisplatin despite the addition of substantial steric bulk to the amine groups, and there was a lack of cross-resistance with cisplatin seen for some compounds.

CHEMICAL COMPOUNDS

The present invention relates generally to novel therapeutic compounds and AXOR 109 agonists, and processes for the manufacture and use of the same.

POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY

The present invention is to provide a novel compound (I), having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. Compound (I) wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.

Synthesis, antitumor activity, and nephrotoxicity of the optical isomers of 2-aminomethylpyrrolidine(1,1-cyclobutane-dicarboxylato) platinum(II)

The optical isomers of 2-aminomethylpyrrolidine(1,1-cyclobutane-dicarboxylato)platinum(II) (DWA2114, 1), which has potent antitumor activity against various tumors, were synthesized. They were examined for antitumor activity against Colon 26 carcinoma in a sc-iv system, and changes in urinary protein and sugar levels in drug-treated mice were used as an index of nephrotoxicity. In their effect on tumors, (+)-(S)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II) (6b) was more potent than the enantiomer 6a in that the effective dose of 6b was smaller than that of 6a; but, both drugs exhibited potent antitumor activity. On the other hand, a distinct difference between 6a and 6b was shown in their nephrotoxicity. Isomer 6b induced a great increase in urinary protein and sugar levels in mice, whereas 6a caused no increase in these levels.

Synthesis and antitumor activities of platinum complexes of unsymmetrical alicyclic diamines as carrier ligands

The synthesis and biological activities of the platinum complexes of 2-aminomethylaziridine, 2-aminomethylazetidine, 2-aminomethylpyrrolidine, and 2-aminomethylpiperidine as carrier ligands are described. The platinum complexes of 2-aminomethylazetidine and 2-aminomethylpyrrolidine are significantly effective against murine tumors. In particular, 2-aminomethylazetidine (1,1-cyclobutanedi-carboxyplato)platinum II (13) and 2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)platinum II (16) exhibited potent antitumor activity and were soluble in water, and their antitumor activities against Colon 26 carcinoma (sc-ip system) were superior to CBDCA and comparable to CDDP.

N-heterocyclic platinum complexes

Novel platinum complexes represented by the formula: STR1 wherein A is alkylene having carbon atoms of from 1 to 3; R1, R2, R3 and R4 are the same or different and are hydrogen or alkyl having carbon atoms of from 1 to 4; X and Y are independently a halogen atom, or combined together to form STR2 and l, m and n are independently 0 or 1, and a process for preparing the same are disclosed. These platinum complexes have high antitumor activity and low toxicity, and are easily soluble in water. Therefore, they are very useful as an antitumor agent.